"10.1371_journal.pone.0081360","plos one","2013-12-09T00:00:00Z","Hui Zhi Low; Sandra Reuter; Michael Topperwien; Nadine Dankenbrink; Dietrich Peest; Gamze Kabalak; Renata Stripecke; Reinhold E Schmidt; Torsten Matthias; Torsten Witte","Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; AESKU.KIPP Institute, Wendelsheim, Germany; AESKU Diagnostics, Wendelsheim, Germany","Conceived and designed the experiments: HZL GK RES TW. Performed the experiments: HZL SR MT ND. Analyzed the data: HZL MT ND. Contributed reagents/materials/analysis tools: SR DP RS TM. Wrote the paper: HZL TW.","One of the coauthors (Torsten Matthias) is employed by the commercial company AESKU Diagnostics. This affiliation has now been declared in the Competing Interests section of the online manuscript. We have also declared, that Torsten Matthias and the senior author (Torsten Witte) are holding a patent on the commercial exploitation of recombinant LILRA3 for the treatment of autoimmune disorders (but not malignancies, which are described in the manuscript). This does not alter the authorsâ€² adherence to all the PLOS ONE policies on sharing data and materials.","2013","12","Hui Zhi Low","HZL",10,TRUE,4,4,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
